<?xml version="1.0" encoding="UTF-8"?>
<ref id="B149-molecules-25-05557">
 <label>149.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Adams</surname>
    <given-names>M.E.</given-names>
   </name>
   <name>
    <surname>Wallace</surname>
    <given-names>M.B.</given-names>
   </name>
   <name>
    <surname>Kanouni</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Scorah</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Oâ€™Connell</surname>
    <given-names>S.M.</given-names>
   </name>
   <name>
    <surname>Miyake</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Shi</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Halkowycz</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Dong</surname>
    <given-names>Q.</given-names>
   </name>
  </person-group>
  <article-title>Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy</article-title>
  <source>Bioorg. Med. Chem. Lett.</source>
  <year>2012</year>
  <volume>22</volume>
  <fpage>2411</fpage>
  <lpage>2414</lpage>
  <pub-id pub-id-type="doi">10.1016/j.bmcl.2012.02.026</pub-id>
  <pub-id pub-id-type="pmid">22406151</pub-id>
 </element-citation>
</ref>
